المؤلفون: Friedrich K. Port, Philip A. McFarlane, Ron Wald, Margaret A. Eichleay, Ronald L. Pisoni, David C. Mendelssohn

المصدر: Kidney International. 78(2):215-223

مصطلحات موضوعية: Nephrology, medicine.medical_specialty, Internationality, Anemia, medicine.medical_treatment, reimbursement mechanisms/economics/legislation & jurisprudence, Reimbursement Mechanisms, Hemoglobins, Pharmacotherapy, Renal Dialysis, health expenditures/trends, Internal medicine, Hemofiltration, medicine, Humans, erythropoietin/ec (Economics), Intensive care medicine, Erythropoietin, Dialysis, Reimbursement, Aged, erythropoietin/ad (Administration & Dosage), business.industry, kidney failure, chronic/blood/economics/therapy, Middle Aged, medicine.disease, Drug Utilization, Hemoglobin, Hemodialysis, business, anemia/dt (Drug Therapy)

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4fce4e39a8cb4e68bc5040e5aa82b84Test

مصطلحات الفهرس: in vitro study, intracellular signaling, iron chelation, male, mouse, myelodysplastic syndrome/dt [Drug Therapy], myelodysplastic syndrome/th [Therapy], myeloid metaplasia/dt [Drug Therapy], myeloid metaplasia/th [Therapy], nonhuman, peripheral blood mononuclear cell, pure red cell anemia/dt [Drug Therapy], pure red cell anemia/th [Therapy], refractory anemia/dt [Drug Therapy], refractory anemia with ringed sideroblasts/dt [Drug Therapy], refractory anemia with ringed sideroblasts/th [Therapy], refractory cytopenia with multilineage dysplasia/dt [Drug Therapy], refractory cytopenia with multilineage dysplasia/th [Therapy], T lymphocyte activation, transcription initiation, treatment duration, treatment response, deferasirox/dt [Drug Therapy], deferasirox/po [Oral Drug Administration], deferasirox/pd [Pharmacology], immunoglobulin enhancer binding protein/ec [Endogenous Compound], tumor necrosis factor/ec [Endogenous Compound], erythroid response, hypoplastic myelodysplastic syndrome/th [Therapy], neutrophil response, platelet response, low risk population, animal cell, antiinflammatory activity, aplastic anemia/dt [Drug Therapy], aplastic anemia/th [Therapy], article, blood transfusion, bone marrow derived macrophage, chelation therapy, chronic lymphatic leukemia/dt [Drug Therapy], chronic lymphatic leukemia/th [Therapy], clinical article, cohort analysis, concentration response, controlled study, cytokine production, cytokine release, drug effect, drug mechanism, female, gene expression regulation, human, human cell, hypoplastic myelodysplastic syndrome/dt [Drug Therapy], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/40861Test
British Journal of Haematology
Click here for full text options
LibKey Link

مصطلحات الفهرس: in vitro study, intracellular signaling, iron chelation, male, mouse, myelodysplastic syndrome/dt [Drug Therapy], myelodysplastic syndrome/th [Therapy], myeloid metaplasia/dt [Drug Therapy], myeloid metaplasia/th [Therapy], nonhuman, peripheral blood mononuclear cell, pure red cell anemia/dt [Drug Therapy], pure red cell anemia/th [Therapy], refractory anemia/dt [Drug Therapy], refractory anemia with ringed sideroblasts/dt [Drug Therapy], refractory anemia with ringed sideroblasts/th [Therapy], refractory cytopenia with multilineage dysplasia/dt [Drug Therapy], refractory cytopenia with multilineage dysplasia/th [Therapy], T lymphocyte activation, transcription initiation, treatment duration, treatment response, deferasirox/dt [Drug Therapy], deferasirox/po [Oral Drug Administration], deferasirox/pd [Pharmacology], immunoglobulin enhancer binding protein/ec [Endogenous Compound], tumor necrosis factor/ec [Endogenous Compound], erythroid response, hypoplastic myelodysplastic syndrome/th [Therapy], neutrophil response, platelet response, low risk population, animal cell, antiinflammatory activity, aplastic anemia/dt [Drug Therapy], aplastic anemia/th [Therapy], article, blood transfusion, bone marrow derived macrophage, chelation therapy, chronic lymphatic leukemia/dt [Drug Therapy], chronic lymphatic leukemia/th [Therapy], clinical article, cohort analysis, concentration response, controlled study, cytokine production, cytokine release, drug effect, drug mechanism, female, gene expression regulation, human, human cell, hypoplastic myelodysplastic syndrome/dt [Drug Therapy], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/40861Test
British Journal of Haematology
LibKey Link

مصطلحات الفهرس: systematic review, albendazole/ct [Clinical Trial], albendazole/cb [Drug Combination], ascorbic acid/ct [Clinical Trial], ascorbic acid/cb [Drug Combination], cyanocobalamin/ct [Clinical Trial], cyanocobalamin/cb [Drug Combination], edetate iron/ct [Clinical Trial], ferric ammonium citrate/ct [Clinical Trial], ferric ammonium citrate/cb [Drug Combination], ferric ammonium citrate/dt [Drug Therapy], ferritin/ec [Endogenous Compound], ferrous sulfate/ct [Clinical Trial], ferrous sulfate/cb [Drug Combination], ferrous sulfate/dt [Drug Therapy], folic acid/ct [Clinical Trial], folic acid/cb [Drug Combination], hemoglobin/ec [Endogenous Compound], iron/ct [Clinical Trial], iron/dt [Drug Therapy], iron/po [Oral Drug Administration], mebendazole/ct [Clinical Trial], mebendazole/cb [Drug Combination], multivitamin/ct [Clinical Trial], multivitamin/cb [Drug Combination], placebo, pyrimethamine/ct [Clinical Trial], pyrimethamine/cb [Drug Combination], retinol/ct [Clinical Trial], retinol/cb [Drug Combination], sulfadoxine/ct [Clinical Trial], sulfadoxine/cb [Drug Combination], transferrin/ec [Endogenous Compound], zinc/ct [Clinical Trial], zinc/cb [Drug Combination], iron deficiency/dt [Drug Therapy], anemia/dt [Drug Therapy], cognitive development, drug safety, growth, hematocrit, human, infection, iron deficiency anemia/dt [Drug Therapy], iron therapy, mean corpuscular volume, meta analysis, priority journal, randomized controlled trial (topic), review, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/27685Test
Click here for full text options
LibKey Link

مصطلحات الفهرس: systematic review, albendazole/ct [Clinical Trial], albendazole/cb [Drug Combination], ascorbic acid/ct [Clinical Trial], ascorbic acid/cb [Drug Combination], cyanocobalamin/ct [Clinical Trial], cyanocobalamin/cb [Drug Combination], edetate iron/ct [Clinical Trial], ferric ammonium citrate/ct [Clinical Trial], ferric ammonium citrate/cb [Drug Combination], ferric ammonium citrate/dt [Drug Therapy], ferritin/ec [Endogenous Compound], ferrous sulfate/ct [Clinical Trial], ferrous sulfate/cb [Drug Combination], ferrous sulfate/dt [Drug Therapy], folic acid/ct [Clinical Trial], folic acid/cb [Drug Combination], hemoglobin/ec [Endogenous Compound], iron/ct [Clinical Trial], iron/dt [Drug Therapy], iron/po [Oral Drug Administration], mebendazole/ct [Clinical Trial], mebendazole/cb [Drug Combination], multivitamin/ct [Clinical Trial], multivitamin/cb [Drug Combination], placebo, pyrimethamine/ct [Clinical Trial], pyrimethamine/cb [Drug Combination], retinol/ct [Clinical Trial], retinol/cb [Drug Combination], sulfadoxine/ct [Clinical Trial], sulfadoxine/cb [Drug Combination], transferrin/ec [Endogenous Compound], zinc/ct [Clinical Trial], zinc/cb [Drug Combination], iron deficiency/dt [Drug Therapy], anemia/dt [Drug Therapy], cognitive development, drug safety, growth, hematocrit, human, infection, iron deficiency anemia/dt [Drug Therapy], iron therapy, mean corpuscular volume, meta analysis, priority journal, randomized controlled trial (topic), review, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/27685Test
LibKey Link

مصطلحات الفهرس: priority journal, pure red cell anemia/dt [Drug Therapy], pure red cell anemia/si [Side Effect], pure red cell anemia/th [Therapy], treatment response, calcineurin inhibitor/cm [Drug Comparison], calcineurin inhibitor/dt [Drug Therapy], continuous erythropoiesis receptor activator/dt [Drug Therapy], corticosteroid derivative/dt [Drug Therapy], cyclophosphamide/cb [Drug Combination], cyclophosphamide/dt [Drug Therapy], cyclosporin/cb [Drug Combination], cyclosporin/dt [Drug Therapy], erythropoietin/ec [Endogenous Compound], immunoglobulin/cm [Drug Comparison], immunoglobulin/dt [Drug Therapy], immunoglobulin/iv [Intravenous Drug Administration], novel erythropoiesis stimulating protein/dt [Drug Therapy], recombinant erythropoietin/ae [Adverse Drug Reaction], recombinant erythropoietin/dt [Drug Therapy], recombinant erythropoietin/iv [Intravenous Drug Administration], recombinant erythropoietin/sc [Subcutaneous Drug Administration], rituximab/dt [Drug Therapy], steroid/cb [Drug Combination], unclassified drug, erypro, steroid/dt [Drug Therapy], anemia/dt [Drug Therapy], chronic kidney disease, disease association, drug withdrawal, editorial, erythrocyte transfusion, graft versus host reaction/dt [Drug Therapy], graft versus host reaction/pc [Prevention], human, immune response, immunosuppressive treatment, nonhuman, plasmapheresis, Editorial

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/31661Test
Click here for full text options
LibKey Link

مصطلحات الفهرس: priority journal, pure red cell anemia/dt [Drug Therapy], pure red cell anemia/si [Side Effect], pure red cell anemia/th [Therapy], treatment response, calcineurin inhibitor/cm [Drug Comparison], calcineurin inhibitor/dt [Drug Therapy], continuous erythropoiesis receptor activator/dt [Drug Therapy], corticosteroid derivative/dt [Drug Therapy], cyclophosphamide/cb [Drug Combination], cyclophosphamide/dt [Drug Therapy], cyclosporin/cb [Drug Combination], cyclosporin/dt [Drug Therapy], erythropoietin/ec [Endogenous Compound], immunoglobulin/cm [Drug Comparison], immunoglobulin/dt [Drug Therapy], immunoglobulin/iv [Intravenous Drug Administration], novel erythropoiesis stimulating protein/dt [Drug Therapy], recombinant erythropoietin/ae [Adverse Drug Reaction], recombinant erythropoietin/dt [Drug Therapy], recombinant erythropoietin/iv [Intravenous Drug Administration], recombinant erythropoietin/sc [Subcutaneous Drug Administration], rituximab/dt [Drug Therapy], steroid/cb [Drug Combination], unclassified drug, erypro, steroid/dt [Drug Therapy], anemia/dt [Drug Therapy], chronic kidney disease, disease association, drug withdrawal, editorial, erythrocyte transfusion, graft versus host reaction/dt [Drug Therapy], graft versus host reaction/pc [Prevention], human, immune response, immunosuppressive treatment, nonhuman, plasmapheresis, Editorial

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/31661Test
LibKey Link

مصطلحات الفهرس: female, gene mutation, graft recipient, haploidentical transplantation, human, induction chemotherapy, letter, leukemia relapse, leukemia remission, male, minimal residual disease, monosomy 7, multiple cycle treatment, myeloblast, myelodysplastic syndrome, pancytopenia/dt [Drug Therapy], priority journal, real time reverse transcription polymerase chain reaction, renal replacement therapy-dependent renal disease, sibling donor, transplantation conditioning, unrelated donor, cyclosporine/dt [Drug Therapy], cyclosporine/tm [Unexpected Outcome of Drug Treatment], cytarabine/dt [Drug Therapy], cytarabine/pv [Special Situation for Pharmacovigilance], DNA methyltransferase 3A/ec [Endogenous Compound], etoposide/dt [Drug Therapy], fludarabine, idarubicin/dt [Drug Therapy], idarubicin/pv [Special Situation for Pharmacovigilance], melphalan, nucleophosmin/ec [Endogenous Compound], thiotepa, thymocyte antibody/dt [Drug Therapy], venetoclax/dt [Drug Therapy], consolidation chemotherapy, CD135 antigen/ec [Endogenous Compound], CD33 antigen/ec [Endogenous Compound], cyclophosphamide, acute myeloid leukemia/dt [Drug Therapy], adult, aged, allogeneic stem cell transplantation, aplastic anemia/dt [Drug Therapy], bone marrow biopsy, cancer chemotherapy, cancer patient, case report, chimera, clinical article, continuous infusion, DNA methylation, dysplasia, Letter

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/27242Test
Leukemia and Lymphoma
Click here for full text options
LibKey Link

مصطلحات الفهرس: female, gene mutation, graft recipient, haploidentical transplantation, human, induction chemotherapy, letter, leukemia relapse, leukemia remission, male, minimal residual disease, monosomy 7, multiple cycle treatment, myeloblast, myelodysplastic syndrome, pancytopenia/dt [Drug Therapy], priority journal, real time reverse transcription polymerase chain reaction, renal replacement therapy-dependent renal disease, sibling donor, transplantation conditioning, unrelated donor, cyclosporine/dt [Drug Therapy], cyclosporine/tm [Unexpected Outcome of Drug Treatment], cytarabine/dt [Drug Therapy], cytarabine/pv [Special Situation for Pharmacovigilance], DNA methyltransferase 3A/ec [Endogenous Compound], etoposide/dt [Drug Therapy], fludarabine, idarubicin/dt [Drug Therapy], idarubicin/pv [Special Situation for Pharmacovigilance], melphalan, nucleophosmin/ec [Endogenous Compound], thiotepa, thymocyte antibody/dt [Drug Therapy], venetoclax/dt [Drug Therapy], consolidation chemotherapy, CD135 antigen/ec [Endogenous Compound], CD33 antigen/ec [Endogenous Compound], cyclophosphamide, acute myeloid leukemia/dt [Drug Therapy], adult, aged, allogeneic stem cell transplantation, aplastic anemia/dt [Drug Therapy], bone marrow biopsy, cancer chemotherapy, cancer patient, case report, chimera, clinical article, continuous infusion, DNA methylation, dysplasia, Letter

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/27242Test
Leukemia and Lymphoma
LibKey Link

مصطلحات الفهرس: aplastic anemia/ep [Epidemiology], aplastic anemia/et [Etiology], aplastic anemia/th [Therapy], blood analysis, blood transfusion, bone marrow examination, clinical feature, disease association, drug efficacy, drug response, drug safety, erythrocyte transfusion, fever/dt [Drug Therapy], fever/si [Side Effect], hematopoietic stem cell transplantation, immunosuppressive treatment, incidence, iron chelation, iron overload/co [Complication], iron overload/dt [Drug Therapy], iron overload/su [Surgery], myelodysplastic syndrome, paroxysmal nocturnal hemoglobinuria, pathogenesis, phlebotomy, priority journal, psychosocial care, quality of life, rash/dt [Drug Therapy], rash/si [Side Effect], relapse, review, thrombocytopenia/dt [Drug Therapy], thrombocytopenia/si [Side Effect], cyclosporine/cb [Drug Combination], cyclosporine/dt [Drug Therapy], deferasirox/dt [Drug Therapy], prednisolone/dt [Drug Therapy], thymocyte antibody/ae [Adverse Drug Reaction], thymocyte antibody/cb [Drug Combination], thymocyte antibody/dt [Drug Therapy], human, acute myeloid leukemia, aplastic anemia/di [Diagnosis], aplastic anemia/dt [Drug Therapy], Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/36226Test
Internal Medicine Journal
Click here for full text options
LibKey Link